None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review
Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter.
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
